Pharma Mar (PHM.MC) Stock Price

Pharma Mar Price

BME·CLOSED
84.40EUR+0.45 (+0.53 %)
Market closed

Revenue has compounded at 5.8% per year over the past 19 years to 221.39 M EUR. Earnings per share have grown at 21.2% per year over the last 13 years. Pharma Mar's net margin stands at 33.9%, down from 40.4% several years earlier. Pharma Mar currently offers a dividend yield of about 0.95%. The payout ratio is around 18% of earnings. The dividend has grown at 32.6% per year over the past 18 years. Analysts set a median price target of 107.10 EUR, implying 26.9% above the current price. Of 13 analysts, 9 rate the stock a buy — an overall Buy consensus. The stock trades about 25% above its 52-week low.

Pharma Mar stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Pharma Mar over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Pharma Mar stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Pharma Mar's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Pharma Mar Stock Price History
DatePharma Mar Price
8/17/202684.40 EUR
8/14/202683.95 EUR
8/13/202684.50 EUR
8/12/202681.95 EUR
8/11/202681.85 EUR
8/10/202680.90 EUR
8/7/202678.40 EUR
8/6/202677.70 EUR
8/5/202677.05 EUR
8/4/202679.10 EUR
7/31/202679.05 EUR
7/30/202679.90 EUR
7/29/202681.00 EUR
7/28/202679.70 EUR
7/27/202680.00 EUR
7/24/202679.30 EUR
7/23/202679.15 EUR
7/22/202678.80 EUR
7/21/202676.25 EUR
7/20/202675.80 EUR
7/17/202675.60 EUR
7/16/202676.00 EUR
7/15/202675.80 EUR
7/14/202676.20 EUR
7/13/202677.35 EUR
7/10/202678.80 EUR
7/9/202682.15 EUR
7/8/202680.95 EUR
7/7/202682.90 EUR
7/6/202681.95 EUR
7/3/202679.15 EUR
7/2/202679.05 EUR
7/1/202675.85 EUR
6/30/202675.45 EUR
6/29/202673.10 EUR
6/26/202673.00 EUR
6/25/202672.90 EUR
6/24/202672.10 EUR
6/23/202669.15 EUR
6/22/202668.75 EUR
6/19/202669.10 EUR
6/18/202670.95 EUR
6/17/202668.55 EUR
6/16/202667.30 EUR
6/15/202670.00 EUR
6/12/202685.75 EUR
6/11/202685.55 EUR
6/10/202682.40 EUR
6/9/202683.80 EUR
6/8/202686.35 EUR
6/5/202699.40 EUR
6/4/202693.40 EUR
6/3/202695.40 EUR
6/2/202699.20 EUR
6/1/2026100.60 EUR
5/29/2026100.70 EUR
5/28/202699.85 EUR
5/27/2026101.30 EUR
5/26/2026101.60 EUR
5/25/2026101.40 EUR
5/22/202699.50 EUR
5/21/202699.65 EUR
5/20/202696.25 EUR
5/19/202694.00 EUR
5/18/202696.10 EUR
5/15/202696.30 EUR
5/14/202697.60 EUR
5/13/202697.30 EUR
5/12/202697.00 EUR
5/11/2026100.30 EUR
5/8/202699.50 EUR
5/7/2026102.80 EUR
5/6/2026103.30 EUR
5/5/2026103.60 EUR
5/4/2026101.30 EUR
4/30/202696.00 EUR
4/29/202697.20 EUR
4/28/202698.65 EUR
4/27/202696.85 EUR
4/24/202694.65 EUR
4/23/202696.95 EUR
4/22/202694.05 EUR
4/21/202693.55 EUR
4/20/202694.80 EUR
4/17/202697.35 EUR
4/16/202697.50 EUR
4/15/202695.90 EUR
4/14/202695.35 EUR
4/13/202692.40 EUR
4/10/202692.90 EUR
4/9/202692.60 EUR
4/8/202689.60 EUR
4/7/202688.60 EUR
4/2/202689.85 EUR
3/27/202688.34 EUR
3/26/202690.65 EUR
3/25/202689.08 EUR
3/24/202686.29 EUR
3/23/202686.18 EUR
3/20/202685.05 EUR
3/19/202684.68 EUR
3/17/202686.66 EUR
3/16/202681.12 EUR
3/13/202679.79 EUR
3/12/202680.80 EUR
3/11/202681.65 EUR
3/10/202682.76 EUR
3/9/202680.11 EUR
3/6/202678.90 EUR
3/5/202681.43 EUR
2/26/202678.46 EUR
2/25/202679.25 EUR
2/23/202678.54 EUR
2/20/202678.73 EUR
2/19/202678.45 EUR
2/18/202678.20 EUR
2/17/202677.24 EUR
2/16/202676.45 EUR
2/13/202676.80 EUR
2/12/202676.30 EUR
2/11/202676.08 EUR
2/10/202677.66 EUR
2/9/202676.81 EUR
2/6/202676.45 EUR
2/5/202676.40 EUR
2/4/202677.48 EUR
2/3/202677.45 EUR
2/2/202676.17 EUR
1/30/202679.00 EUR
1/29/202678.51 EUR
1/28/202679.07 EUR
1/27/202679.85 EUR
1/26/202681.48 EUR
1/23/202681.90 EUR
1/22/202680.83 EUR
1/21/202679.10 EUR
1/20/202679.31 EUR
1/19/202680.14 EUR
1/16/202681.00 EUR
1/15/202682.00 EUR
1/14/202681.79 EUR
1/13/202679.75 EUR
1/12/202680.95 EUR
1/9/202679.63 EUR
1/8/202677.94 EUR
1/7/202678.62 EUR
1/6/202676.07 EUR
1/5/202675.38 EUR
1/2/202676.66 EUR
12/31/202574.90 EUR
12/30/202574.69 EUR
12/29/202576.61 EUR
12/24/202576.30 EUR
12/23/202576.00 EUR
12/22/202575.75 EUR
12/19/202576.24 EUR
12/18/202573.84 EUR
12/17/202574.36 EUR
12/16/202573.99 EUR
12/15/202575.71 EUR
12/12/202576.22 EUR
12/11/202575.51 EUR
12/10/202574.45 EUR
12/9/202575.05 EUR
12/8/202575.84 EUR
12/5/202575.59 EUR
12/4/202575.12 EUR
12/3/202573.50 EUR
12/2/202573.03 EUR
12/1/202574.16 EUR
11/28/202575.31 EUR
11/27/202577.99 EUR
11/26/202577.52 EUR
11/25/202576.98 EUR
11/24/202578.25 EUR
11/21/202576.03 EUR
11/20/202577.73 EUR
11/19/202576.65 EUR
11/18/202575.06 EUR
11/17/202575.03 EUR
11/14/202574.77 EUR
11/13/202575.50 EUR
11/12/202574.27 EUR
11/11/202571.39 EUR
11/10/202571.49 EUR
11/7/202571.18 EUR
11/6/202571.77 EUR
11/5/202571.93 EUR
11/4/202573.52 EUR
11/3/202573.34 EUR
10/31/202573.97 EUR
10/30/202573.83 EUR
10/29/202574.49 EUR
10/28/202574.76 EUR
10/27/202575.17 EUR
10/24/202574.09 EUR
10/23/202576.14 EUR
10/22/202576.56 EUR
10/21/202577.47 EUR
10/20/202578.73 EUR
10/17/202579.71 EUR
10/16/202581.07 EUR
10/15/202581.09 EUR
10/14/202582.66 EUR
10/13/202586.32 EUR
10/10/202586.66 EUR
10/9/202586.32 EUR
10/8/202587.50 EUR
10/7/202589.68 EUR
10/6/202591.35 EUR
10/3/202595.47 EUR
10/2/202592.98 EUR
10/1/202594.78 EUR
9/29/202588.20 EUR
9/26/202586.50 EUR
9/25/202586.80 EUR
9/24/202588.97 EUR
9/23/202588.57 EUR
9/22/202588.23 EUR
9/19/202588.70 EUR
9/18/202588.34 EUR
9/17/202590.96 EUR
9/16/202588.07 EUR
9/15/202586.60 EUR
9/12/202589.33 EUR
9/11/202585.38 EUR
9/10/202585.98 EUR
9/9/202584.32 EUR
9/8/202588.38 EUR
9/5/202589.21 EUR
9/4/202590.88 EUR
9/3/202587.57 EUR
9/2/202584.41 EUR
9/1/202584.00 EUR
8/29/202581.75 EUR
8/28/202581.47 EUR
8/27/202580.20 EUR
8/26/202580.84 EUR
8/25/202581.58 EUR
8/22/202582.28 EUR
8/21/202580.53 EUR
8/20/202579.97 EUR
8/19/202580.70 EUR
8/18/202584.08 EUR
Access this data via the Eulerpool API
Get Free API Key

Pharma Mar Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
158.15 M EUR
-3.83 M EUR
1.14 M EUR
Jan 1, 2024
174.86 M EUR
6.47 M EUR
26.13 M EUR
Jan 1, 2025
221.39 M EUR
40.28 M EUR
74.99 M EUR
Jan 1, 2026 (e)
217.95 M EUR
38.97 M EUR
41.53 M EUR
Jan 1, 2027 (e)
299.53 M EUR
53.76 M EUR
108.61 M EUR
Jan 1, 2028 (e)
385.67 M EUR
71.02 M EUR
178.11 M EUR
Jan 1, 2029 (e)
422.78 M EUR
77.85 M EUR
204.60 M EUR
Jan 1, 2030 (e)
528.73 M EUR
97.36 M EUR
295.28 M EUR

Pharma Mar Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 18, 2026, 8:21 AM
 
REVENUEM EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
DIV.EUR
DIV. GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
192.00180.00179.00162.0085.00269.00229.00196.00158.00174.00221.00217.00299.00385.00422.00528.00
29.73-6.25-0.56-9.50-47.53216.47-14.87-14.41-19.3910.1327.01-1.8137.7928.769.6125.12
76.5675.5674.3077.7894.1295.1793.0192.8693.6795.4094.5794.5794.5794.5794.5794.57
147.00136.00133.00126.0080.00256.00213.00182.00148.00166.00209.00205.22282.76364.10399.09499.33
11.00-19.00-17.00-14.00-17.00155.0098.0044.00-3.006.0040.0038.0053.0071.0077.0097.00
5.73-10.56-9.50-8.64-20.0057.6242.7922.45-1.903.4518.1017.5117.7318.4418.2518.37
6.00-24.00-26.00-5.00-9.00137.0092.0049.001.0026.0074.0041.00108.00178.00204.00295.00
-53.85-500.008.33-80.7780.00-1,622.22-32.85-46.74-97.962,500.00184.62-44.59163.4164.8114.6144.61
–––––0.040.600.650.650.650.800.890.981.09––
––––––1,400.008.33––23.0811.2510.1111.22––
18.4418.4218.4318.4618.4918.1518.0118.0117.6417.6417.2117.2117.2117.2117.2117.21
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Pharma Mar generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Pharma Mar retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Pharma Mar's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Pharma Mar has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Pharma Mar's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Pharma Mar stock margins

The Pharma Mar margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Pharma Mar. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Pharma Mar.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
92.85 %
42.86 %
40.40 %
Jan 1, 2022
93.05 %
22.45 %
25.14 %
Jan 1, 2023
93.92 %
-2.42 %
0.72 %
Jan 1, 2024
95.32 %
3.70 %
14.94 %
Jan 1, 2025
94.46 %
18.19 %
33.87 %
Jan 1, 2026 (e)
94.46 %
17.88 %
19.06 %
Jan 1, 2027 (e)
94.46 %
17.95 %
36.26 %
Jan 1, 2028 (e)
94.46 %
18.41 %
46.18 %

Pharma Mar Stock Revenue, EBIT, Earnings per Share

The Pharma Mar earnings per share therefore indicates how much revenue Pharma Mar has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
12.76 EUR
5.47 EUR
5.16 EUR
Jan 1, 2022
10.90 EUR
2.45 EUR
2.74 EUR
Jan 1, 2023
8.97 EUR
-0.22 EUR
0.06 EUR
Jan 1, 2024
9.91 EUR
0.37 EUR
1.48 EUR
Jan 1, 2025
12.86 EUR
2.34 EUR
4.36 EUR
Jan 1, 2026 (e)
12.41 EUR
2.26 EUR
2.37 EUR
Jan 1, 2027 (e)
17.06 EUR
3.12 EUR
6.18 EUR
Jan 1, 2028 (e)
21.96 EUR
4.13 EUR
10.14 EUR

Pharma Mar business model & stock analysis

Pharma Mar SA is a biopharmaceutical company based in Madrid, Spain, focused on developing and marketing innovative cancer treatments. The company originated from Zeltia SA, a business group founded in 1963 that was previously active in various sectors including shipbuilding and fishing. In 1986, Zeltia SA expanded into the pharmaceutical industry and established Pharma Mar SA to concentrate on researching and developing cancer therapies. Over the years, Pharma Mar SA expanded its portfolio through acquisitions and partnerships, such as the acquisition of the biotech company Sylentis in 2006 and a strategic collaboration with Janssen Pharmaceutica in 2014. Today, Pharma Mar SA's business model consists of researching, developing, and marketing cancer treatments based on marine organisms. The company has built an extensive library of marine organisms from which it identifies and develops potential compounds for cancer therapy. Pharma Mar SA is divided into three main business areas: oncology, ophthalmology, and diagnostics. The oncology division focuses on developing and marketing drugs for the treatment of various types of cancer, such as lung cancer, breast cancer, ovarian cancer, and small cell lung cancer. One of Pharma Mar SA's key products in the oncology field is Yondelis, a medication for the treatment of soft tissue sarcomas and ovarian cancer. Yondelis was developed by Pharma Mar SA in collaboration with Janssen Pharmaceutica and is the first medication approved by the European Medicines Agency for the treatment of soft tissue sarcomas. The ophthalmology division focuses on researching and developing drugs for the treatment of eye diseases such as dry eye and retinitis pigmentosa. Pharma Mar SA has a promising pipeline of products in early development, including p118, a compound for the treatment of dry eye that is currently being tested in clinical trials. The diagnostics division focuses on the development of innovative diagnostics for the early detection of cancer and other diseases. Pharma Mar SA has a range of products in development, including a blood test for the detection of lung cancer based on the identification of tumor markers. Overall, Pharma Mar SA has an impressive track record in the development and marketing of cancer treatments from marine organisms. The company has launched several products that contribute to improving the lives of cancer patients and has a promising pipeline of products in development that have the potential to revolutionize the treatment of cancer and other diseases.

Pharma Mar SWOT Analysis

Strengths

Pharma Mar SA possess several strengths that contribute to its success in the pharmaceutical industry. These strengths include:

  • Strong and diverse portfolio of innovative and effective products.
  • Advanced research and development capabilities.
  • Strong brand reputation and market presence.
  • Solid financial performance and stable revenue growth.
  • Effective strategic partnerships with key stakeholders.

Despite its strengths, Pharma Mar SA also faces certain weaknesses that may hinder its growth and competitiveness. These weaknesses include:

  • Reliance on a few core products for a significant portion of its revenue.
  • Limited geographic presence and market diversification.
  • Potential vulnerability to changes in regulatory environment.
  • Dependency on external suppliers for key ingredients.
  • High research and development costs, which may impact profitability.

There are several opportunities available for Pharma Mar SA to capitalize on and further enhance its position in the market, including:

  • Increasing demand for innovative cancer treatments globally.
  • Expansion into new geographic markets to capture untapped potential.
  • Growing trend towards personalized medicine and targeted therapies.
  • Potential partnerships and collaborations with research institutions and pharmaceutical companies.
  • Advancements in technology that could enhance drug development process.

Pharma Mar SA also faces certain threats that may pose challenges to its growth and profitability, such as:

  • Intense competition from established pharmaceutical companies.
  • Potential emergence of generic alternatives to its products.
  • Regulatory uncertainties and strict compliance requirements.
  • Increasing cost pressures from healthcare payers.
  • Intellectual property infringements and patent expirations.

Weaknesses

Despite its strengths, Pharma Mar SA also faces certain weaknesses that may hinder its growth and competitiveness. These weaknesses include:

  • Reliance on a few core products for a significant portion of its revenue.
  • Limited geographic presence and market diversification.
  • Potential vulnerability to changes in regulatory environment.
  • Dependency on external suppliers for key ingredients.
  • High research and development costs, which may impact profitability.

There are several opportunities available for Pharma Mar SA to capitalize on and further enhance its position in the market, including:

  • Increasing demand for innovative cancer treatments globally.
  • Expansion into new geographic markets to capture untapped potential.
  • Growing trend towards personalized medicine and targeted therapies.
  • Potential partnerships and collaborations with research institutions and pharmaceutical companies.
  • Advancements in technology that could enhance drug development process.

Pharma Mar SA also faces certain threats that may pose challenges to its growth and profitability, such as:

  • Intense competition from established pharmaceutical companies.
  • Potential emergence of generic alternatives to its products.
  • Regulatory uncertainties and strict compliance requirements.
  • Increasing cost pressures from healthcare payers.
  • Intellectual property infringements and patent expirations.

Opportunities

There are several opportunities available for Pharma Mar SA to capitalize on and further enhance its position in the market, including:

  • Increasing demand for innovative cancer treatments globally.
  • Expansion into new geographic markets to capture untapped potential.
  • Growing trend towards personalized medicine and targeted therapies.
  • Potential partnerships and collaborations with research institutions and pharmaceutical companies.
  • Advancements in technology that could enhance drug development process.

Pharma Mar SA also faces certain threats that may pose challenges to its growth and profitability, such as:

  • Intense competition from established pharmaceutical companies.
  • Potential emergence of generic alternatives to its products.
  • Regulatory uncertainties and strict compliance requirements.
  • Increasing cost pressures from healthcare payers.
  • Intellectual property infringements and patent expirations.

Threats

Pharma Mar SA also faces certain threats that may pose challenges to its growth and profitability, such as:

  • Intense competition from established pharmaceutical companies.
  • Potential emergence of generic alternatives to its products.
  • Regulatory uncertainties and strict compliance requirements.
  • Increasing cost pressures from healthcare payers.
  • Intellectual property infringements and patent expirations.

Pharma Mar Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Pharma Mar historical P/E ratio, EBIT multiple, and P/S ratio

Pharma Mar annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Pharma Mar shares outstanding

The number of shares of Pharma Mar was 17.21 M in 2025. This indicates how many shares Pharma Mar is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
18.01 M Stocks
Jan 1, 2022
18.01 M Stocks
Jan 1, 2023
17.64 M Stocks
Jan 1, 2024
17.64 M Stocks
Jan 1, 2025
17.21 M Stocks
Jan 1, 2026 (e)
17.21 M Stocks
Jan 1, 2027 (e)
17.21 M Stocks
Jan 1, 2028 (e)
17.21 M Stocks

Pharma Mar stock splits

In Pharma Mar's history, there have been no stock splits.

Pharma Mar Dividend History

21 years of dividend payments

YearAnnual DividendYoY ChangePayments
20250.80EUR↑ 23.1%1×
Jun 25, 20250.80EUR↑ 23.1%1/1
20240.65EUR 0.0%1×
20230.65EUR 0.0%1×
20220.65EUR↑ 8.3%1×
20210.60EUR↑ 1,400.0%1×
20200.04EUR↑ 700.0%1×
20080.01EUR 0.0%1×
20070.01EUR↓ 50.0%1×
20040.01EUR 0.0%1×
20020.01EUR↓ 44.5%1×

Pharma Mar dividend history and estimates

In 2025, Pharma Mar paid a dividend amounting to 0.80 EUR. Dividend means that Pharma Mar distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021
0.60 EUR
0.00 EUR
Jan 1, 2022
0.65 EUR
0.00 EUR
Jan 1, 2023
0.65 EUR
0.00 EUR
Jan 1, 2024
0.65 EUR
0.00 EUR
Jan 1, 2025
0.80 EUR
0.00 EUR
Jan 1, 2026 (e)
0.00 EUR
0.89 EUR
Jan 1, 2027 (e)
0.00 EUR
0.98 EUR
Jan 1, 2028 (e)
0.00 EUR
1.09 EUR

Pharma Mar dividend payout ratio

In 2025, Pharma Mar had a payout ratio of 18.36%. The payout ratio indicates the percentage of the company's profits that Pharma Mar distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
11.64 %
Jan 1, 2022
23.72 %
Jan 1, 2023
1,008.44 %
Jan 1, 2024
43.89 %
Jan 1, 2025
18.36 %
Jan 1, 2026 (e)
37.47 %
Jan 1, 2027 (e)
15.87 %
Jan 1, 2028 (e)
10.72 %

Current Pharma Mar forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
69.23 % (9)
Hold
23.08 % (3)
Sell
7.69 % (1)
12M Price Target
107.10
Last Price
83.95
Currency
EUR
12M Return Potential
27.58 %
LTM Return
0 %

Pharma Mar Earnings Calls

Pharma Mar Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
7/26/2018-0.36EUR-84.65 MEUR-2018 Q2

EESG©

Eulerpool ESG Scorecard© for the Pharma Mar stock

75/100
99
Environment
99
Social
28
Governance
E

Environment

20
Scope 1 - Direct Emissions1,233
Scope 2 - Indirect emissions from purchased energy1,359
Scope 3 - Indirect emissions within the value chain15,876
Total CO₂ emissions2,592
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees61.5
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Pharma Mar shareholder structure

% Name
11.79927%
Fernandez Sousa Faro (Jose Maria)
Fernandez Sousa Faro (Jose Maria)
5.44707%
Andrade Detrell (Montserrat)
Andrade Detrell (Montserrat)
5.28135%
Ortega Mera (Sandra)
Ortega Mera (Sandra)
5.22708%
Fernandez Puentes (Pedro Francisco)
Fernandez Puentes (Pedro Francisco)
2.61736%
JPMorgan Chase & Co
JPMorgan Chase & Co
2.18772%
The Vanguard Group, Inc.
The Vanguard Group, Inc.

Pharma Mar Beneficial Ownership Filings (SEC 13D/G)

Free Float
77.5%
Float Shares
-
Shares Outstanding
-

Pharma Mar Executives and Management Board

20 members · avg. age 77 · 45 % women

PP

Mr. Pedro Francisco Fernandez Puentes

Executive Vice Chairman of the Board

573,000.00 EUR

Management

MC

Ms. Maria Luisa de Francia Caballero

Chief Financial Officer

–
SS

Ms. Sandra Llamera Sanchez

Global Chief Compliance Officer

–
ML

Ms. Maria Concepcion Sanz Lopez

General Counsel to Business

–
LC

Mr. Luis Mora Capitan

General Manager - Oncology Business Unit · since 2024

–
JG

Mr. Juan Carlos Villalon Gomez

Internal Auditor

–

Board of Directors

JS

Mr. Jose Maria Fernandez Sousa-Faro

Executive Chairman of the Board · since 2023

3.24 M EUR
MD

Ms. Montserrat Andrade Detrell

Proprietary Director

273,000.00 EUR
FS

Mr. Fernando Martin-Delgado Santos

Other External Director

242,000.00 EUR
SM

Ms. Soledad Cuenca Miranda

Independent Director

160,000.00 EUR
MR

Ms. Maria Blanca Hernandez Rodriguez

Independent Director

156,000.00 EUR
RA

Ms. Rosa Maria Sanchez-Yebra Alonso

Independent Director

131,000.00 EUR

Frequently asked questions about Pharma Mar

The business model of Pharma Mar SA revolves around the research, development, and commercialization of innovative marine-derived pharmaceutical products. Pharma Mar specializes in the development of therapies derived from marine resources, particularly marine microorganisms. By harnessing the therapeutic potential of the sea, the company aims to bring effective treatments to patients suffering from various diseases, including cancer. With a focus on oncology, Pharma Mar seeks to address unmet medical needs and improve patients' lives globally. Through strategic partnerships, clinical trials, and ongoing research, Pharma Mar continues to drive advancements in the field of marine-derived pharmaceuticals.

Pharma Mar SA is primarily active in the pharmaceutical industry.

The main competitors of Pharma Mar SA in the market include other pharmaceutical companies operating in the same field and targeting similar market segments. Some notable competitors of Pharma Mar SA may include (examples only, not an exhaustive list): AstraZeneca, Novartis, Roche Holding, Pfizer, and Johnson & Johnson. These companies also focus on researching, developing, and marketing pharmaceutical products, including therapies and treatment options.

Pharma Mar SA is a leading biopharmaceutical company with a rich history and background. Established in 1986, the company is headquartered in Madrid, Spain. Pharma Mar SA focuses on the research, development, and commercialization of innovative marine-derived drugs to address various oncology and rare diseases. With a strong commitment to scientific excellence, Pharma Mar SA has built a diverse pipeline of potential therapies, leveraging the unique properties of marine organisms. The company has garnered global recognition for its breakthrough discovery of marine-derived compounds, including the development of Aplidin® (plitidepsin), a promising anticancer agent undergoing clinical trials. Pharma Mar SA continues to push boundaries in the pharmaceutical industry, striving to improve patients' lives worldwide.

Pharma Mar SA, a leading pharmaceutical company, has achieved significant milestones in its remarkable journey. The company's innovative approach and dedication to drug discovery have yielded remarkable results. Pharma Mar SA's milestones include successful clinical trials for their flagship drugs, receiving regulatory approvals, and securing strategic partnerships with renowned pharmaceutical companies. Furthermore, the company's consistent commitment to scientific research and development has resulted in groundbreaking discoveries that have revolutionized the treatment of various diseases. Through their remarkable achievements, Pharma Mar SA has solidified its position as a pioneering force in the pharmaceutical industry and continues to make invaluable contributions towards improving global healthcare.

Pharma Mar SA is primarily present in several countries and regions. The company has a strong presence in Spain, where it is based and operates its headquarters. Additionally, Pharma Mar SA has expanded its operations to various international markets, including the United States, Germany, Italy, France, and Switzerland. With a global presence, Pharma Mar SA strives to bring its innovative pharmaceutical products and treatments to patients worldwide.

Pharma Mar SA represents a set of core values and corporate philosophy that drive its operations. The company focuses on developing innovative therapies in the field of oncology and the treatment of other serious diseases. With a commitment to scientific excellence, Pharma Mar SA aims to create impactful solutions that improve patients' lives. Through strategic collaborations and continuous research, the company strives to deliver cutting-edge pharmaceutical products. Pharma Mar SA's dedication to ethical practices, transparency, and sustainability further reinforces its commitment to stakeholders and the global healthcare community.

Analysts currently set an average price target of 99.84 EUR for the Pharma Mar stock (median: 107.10 EUR), implying +18.9 % versus the latest price. The consensus is based on 13 analyst ratings.

Pharma Mar Analyst Price Targets 2026

13 analysts currently rate the Pharma Mar stock: 9 recommend buying, 3 holding and 1 selling. For 2026, analysts expect Pharma Mar to generate revenue of 217.95 M EUR and earnings per share of 2.41 EUR.

Pharma Mar Analyst Price Targets 2026

The Pharma Mar share (PHM.MC) is listed on 7 stock exchanges, including: Frankfurt (PMRA.F), München (PMRA.MU), Düsseldorf (PMRA.DU), London (0RC6.L).

Pharma-Mar SA is a Spanish pharmaceutical company specializing in the development and marketing of cancer therapies. The company was founded in 1986 and is based in Colmenar Viejo, near Madrid. The company consists of two different business areas: Oncology and Consumer Healthcare. The Oncology division focuses on the development and marketing of innovative cancer drugs based on marine compounds, while the Consumer Healthcare division distributes over-the-counter drugs and cosmetic products. The company's business model is based on a strong research and development department that specializes in the exploration and development of cancer drugs based on marine compounds. They also collaborate with other pharmaceutical companies and research institutions to advance the research and development of cancer drugs. The company has a strong presence in international markets and has distribution partnerships in Europe, America, and Asia, allowing them to market their products worldwide and increase their revenue. Overall, Pharma-Mar SA is dedicated to the research, development, and distribution of cancer drugs, as well as over-the-counter drugs and cosmetic products.

The expected revenue of Pharma Mar is 217.95 M EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Pharma Mar is 41.53 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Pharma Mar is currently 34.97. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Pharma Mar stock.

The price-to-sales ratio (P/S) of Pharma Mar is currently 6.66. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Pharma Mar stock.

The Eulerpool Quality Score for Pharma Mar is 3/10.

The ISIN of Pharma Mar is ES0169501022. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Pharma Mar is A2P9YT. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Pharma Mar is PHM.MC. The ticker symbol is used to trade Pharma Mar shares on the stock exchange.

Over the past 12 months, Pharma Mar paid a dividend of 0.80 EUR . This corresponds to a dividend yield of about 0.95 %. For the coming 12 months, Pharma Mar is expected to pay a dividend of 0.98 EUR.

The current dividend yield of Pharma Mar is 0.95 %.

Pharma Mar pays a dividend, distributed in the months of , , , .

Pharma Mar paid dividends every year for the past 6 years.

For the upcoming 12 months, dividends amounting to 0.98 EUR are expected. This corresponds to a dividend yield of 1.16 %.

Pharma Mar is assigned to the 'Health' sector.

To receive the latest dividend of Pharma Mar from amounting to 0.8 EUR, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Pharma Mar distributed 0.65 EUR as dividends.

The dividends of Pharma Mar are distributed in EUR.

All fundamentals and in-depth analysis of Pharma Mar

Our stock analysis for Pharma Mar stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pharma Mar. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Pharma Mar Stock
Pharma Mar Revenue→
Pharma Mar Stock
Pharma Mar Net Income→
Pharma Mar Stock
Pharma Mar P/E→
Pharma Mar Stock
Pharma Mar P/S→
Pharma Mar Stock
Pharma Mar EBIT→
Pharma Mar Stock
Pharma Mar Dividend→
Pharma Mar Stock
Pharma Mar Directors Dealings→
Pharma Mar Stock
Pharma Mar Stocks→
Pharma Mar Stock
Pharma Mar Market capitalization→
Pharma Mar Stock
Pharma Mar Debt→
Pharma Mar Stock
Pharma Mar Liabilities→
Pharma Mar Stock
Pharma Mar Equity→
Pharma Mar Stock
Pharma Mar AAQS→
Pharma Mar Stock
Pharma Mar Employees→
Pharma Mar Stock
Pharma Mar ROE→
Pharma Mar Stock
Pharma Mar ROA→
Pharma Mar Stock
Pharma Mar ROCE→
Pharma Mar Stock
Pharma Mar News→
Pharma Mar Stock
Pharma Mar Analyst Price Targets→

Health Stocks

Pharma-Bio ServPharma Foods International CoPharmaBlock Sciences NanjingPhapros Tbk PTPharmacieloPhaarmasiaPharmacom BiovetPfizerPharmaCyte BiotechPfizerPharmaEnginePetVivo HoldingsAll Stocks A–Z →